Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes.
By R. Salem, R. Lewandowski, M. Mulcahy, A. Riaz, R. Ryu, S. Ibrahim, Bassel Atassi, Talia B. Baker, V. Gates, F. Miller and 8 more. Gastroenterology, 2010
1,037 citations recorded by the source corpus.
Subfields: Hepatology, Surgery
View Paper: https://www.semanticscholar.org/paper/3d12deb60e771682151a1ea48ee9a40f5716c51d
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hepatology
- J. Llovet
- Jordi Bruix1 , 2
- Riccardo Lencioni
- V. Mazzaferro
- Alejandro Forner1 , 2
- Andrew X. Zhu
- Peter R. Galle
- T. de Baère
In Surgery
Citations in the corpus
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. (2018, background): “Objective response rates range from 35% to 50%.(382,552,554) Around 20% of patients present liver-related toxicity and 3% treatment-related death,(552) but adverse events are neither more common nor more severe in elderly patients, and survival is no shorter.”
- Survival after yttrium‐90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation (2011, background): “Although a head-tohead comparison of chemoembolization and radioembolization among patients in the intermediate stage is probably unfeasible due to the large number of patients needed (>1,000 according to Salem et al.31), radioembolization should be tested in the advanced stage either alone or, more”
- Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma (2012, background): “The objective response rate is comparable to that of other catheter-based modalities and depends on several factors including the size of the lesion, pattern of spread within the liver (unilobular vs bilobular), and vascularity of the lesion noted on planning arteriogram.(30) In patients with limite”
- Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma (2010, neutral): “81 RFA 6 (5) 8 (7) Resection 4 (3) 3 (2) Imaging characteristics Portal hypertension Present 98 (80) 90 (73) .”
- EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012, background): “Around 20% of patients present liver-related toxicity and 3% treatment-related death [297].”
- EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012, background): “Around 20% of patients present liver-related toxicity and 3% treatment-related death [297].”